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ABSTRACT
Purpose: Interleukin-10 (IL-10) may play an important
role in controlling tumor growth and metastasis. Some re-
ports have shown that IL-10 can be a potent inhibitor of
tumor growth, but others suggest that IL-10 expression by
the tumor is an adverse prognostic factor. Because normal
bronchial epithelial cells constitutively produce IL-10, we
decided to test the prognostic value of IL-10 in a well-
defined population of patients with stage I non-small cell
lung cancer (NSCLC) treated in a single institution.
Patients and Methods: Using immunohistochemical
analysis, we retrospectively analyzed IL-10 expression in
specimens from 138 patients with completely resected clin-
ical/radiographic stage I NSCLC for whom clinical
follow-up data were available.
Results: IL-10 expression was retained (IL-10 labeling
index > 10%) in 94 patients (68.1%) and lost in 44 patients
(31.9%). The duration of overall, disease-specific, and
disease-free survival in the 44 patients lacking IL-10 expres-
sion was worse than in the 94 patients with IL-10 expression
(P  0.08, 0.02, and 0.05, respectively; Log-rank test). In-
terestingly, IL-10 expression was observed more frequently
in tumors with squamous cell histology than in tumors of
other histological subtypes (P  0.04; 2 test). Multivariate
analysis confirmed the independent prognostic value of
IL-10 expression for disease-specific survival (P  0.04).
Conclusion: Lack of IL-10 expression by the tumor was
associated with a significantly worse outcome of early stage
NSCLC. The mechanisms underlying this clinically and bi-
ologically important finding need to be further explored.
INTRODUCTION
Lung cancer is a major cause of mortality worldwide. Last
year, in the United States alone, an estimated 169,400 new cases
of lung cancer were diagnosed, and an estimated 154,900 deaths
from lung cancer occurred (1). Improving the survival rate of
patients with this disease requires a better understanding of
tumor biology and the subsequent development of novel thera-
peutic strategies. One area of intense lung cancer research has
been in assessing the prognostic factors of NSCLC,3 focusing on
stage I disease and molecular factors (2–5). This avenue of
investigation may lead to the identification of patients with the
highest risk stage I NSCLC or of those who are most likely to
benefit from adjuvant or chemopreventive approaches.
IL-10 is thought to play a potential pathogenic or thera-
peutic role in a number of human conditions, such as inflam-
mation, autoimmunity, and cancer (6). The immunomodulatory
effects of IL-10 have yielded mixed results in various tumor
systems. On one hand, because many tumor types express IL-10,
its role in helping tumors evade immunosurveillance has been
suggested (7, 8). IL-10 inhibits the tumoricidal capacity of
macrophages and the cytotoxicity and cytokine production of
tumor-specific T cells and blocks the presentation of tumor
antigens by antigen-presenting cells (9, 10). On the other hand,
in vivo studies in different animal models have demonstrated
that IL-10 is a potent inhibitor of tumor growth and metastasis
(11–14). Additionally, systemic administration of IL-10 has
inhibited tumor metastasis and stimulated antitumor immune
responses in murine models (15). Nevertheless, recent data
generated by analyzing human lung tissue samples suggest that
IL-10 produced by NSCLC is a predictor of poor outcome (16).
Because IL-10 is constitutively expressed in normal bron-
chial epithelial cells, we hypothesized that loss of IL-10 expres-
sion by lung tumors might be a prognostic factor for survival.
Therefore, we decided to analyze the prognostic value of IL-10
expression in a homogeneous population of 138 patients with
stage I NSCLC.
PATIENTS AND METHODS
Study Population. A total of 595 consecutive patients
with stage I NSCLC underwent definitive surgical resection,
defined as a lobectomy or a pneumonectomy, from 1975 to 1990
Received 8/12/02; revised 1/22/02; accepted 1/28/03.
The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
1 Supported by Biology, Education, Screening, Chemoprevention, and
Treatment Lung Cancer Program, Department of Defense Grant
DAMD17-01-1-0689-1 (to F. R. K. and L. M.), Cancer Center Grant
P30 CA 16620 (to M. D. Anderson Cancer Center), Tobacco Research
Fund from the State of Texas (to M. D. Anderson Cancer Center),
American Cancer Society Grant RPG-98-054 (to L. M.), and Fondation
de France, AP-HP, and Lilly Foundation Grant (to J-C. S.).
2 To whom requests for reprints should be addressed, at Winship Cancer
Institute, 1365 Clifton Road, Suite B4100, Atlanta, GA 30322. Phone:
(404) 778-4250; Fax: (404) 778-5016; E-mail: fkhuri@emory.edu.
3 The abbreviations used are: NSCLC, non-small cell lung cancer; SCC,
squamous cell carcinoma; TNM, Tumor-Node-Metastasis; CI, confi-
dence interval; IL, interleukin; TIMP, tissue inhibitor of metallopro-
tease; NK, natural killer; MMP, matrix metalloprotease.
1785Vol. 9, 1785–1791, May 2003 Clinical Cancer Research
Research. 
on July 20, 2014. © 2003 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
at The University of Texas M. D. Anderson Cancer Center. We
retrospectively examined 138 cases for which both tissue sam-
ples and a median follow-up period of 5 years were available
at the time of this study. The patient population was identified
through a search of the Tumor Registry database maintained by
the Department of Medical Informatics at The University of
Texas M. D. Anderson Cancer Center. Survival status was ver-
ified and updated from Tumor Registry records as of December
1, 2000.
The study population consisted of 106 men and 32 women;
120 patients were Caucasian, and 18 patients were of other
ethnicities (Table 1). The mean age of patients at surgery was 63
years. Histological subtypes included 58 cases of SCC, 60 cases
of adenocarcinoma, 10 cases of bronchioalveolar carcinoma, 5
cases of large cell carcinoma, 3 cases of adenosquamous carci-
noma, and 2 cases unclassified.
Immunohistochemical Staining for IL-10 Protein. All
available tissue blocks from each patient were reviewed for the
presence of tumor by a thoracic pathologist (B. L. K.). Paraffin-
embedded, 4-m-thick tissue sections from all 154 primary
tumors were stained for IL-10 protein using a primary goat
polyclonal antihuman IL-10 antibody (AF-217-NA; R&D Sys-
tems, Minneapolis, MN). Slides were deparaffinized through a
series of xylene baths. Rehydration was performed using graded
alcohol. The sections were then immersed in methanol contain-
ing 0.3% hydrogen peroxidase for 20 min to block the endog-
enous peroxidase activity and incubated in 2.5% blocking serum
to reduce nonspecific binding. Sections were incubated over-
night at 4°C with primary anti-IL-10 antibody at a dilution of
1:75 (1.33 g/ml). The sections were then processed using a
standard avidin-biotin immunohistochemical assay according to
the manufacturer’s recommendations (Vector Laboratories, Bur-
lingame, CA). Diaminobenzidine was used as a chromogen, and
commercial hematoxylin was used for counterstaining. Rou-
tinely processed tissue sections of normal lymph nodes and
tonsils were used as positive staining controls and also stained
with the primary antibody omitted to confirm staining specific-
ity. Normal bronchial epithelial cells that constitutively produce
IL-10 were also used as internal positive controls (17).
The IL-10 labeling index was defined as the percentage of
tumor cells displaying cytoplasmic immunoreactivity and cal-
culated by counting IL-10-stained tumor cells among 1000
tumor cells for each section. Representative areas of each tissue
section were selected, and cells were counted in at least four
fields (magnified 400 times) in these areas. On the basis of
previous reports, if 10% of the tumor cells were positive for
IL-10, the case was considered to be IL-10 positive (18, 19).
Tumors with 10% of the cells stained were counted as nega-
tive. All slides were scored concomitantly by a pathologist
(X. T.) and another investigator (J-C. S.). Immunohistochemical
analysis was performed in a blinded manner with respect to
clinical information about the subjects.
Statistical Analysis. Overall, disease-specific, and
disease-free survival were analyzed in this study. Survival
curves were estimated by the Kaplan-Meier method. The Log-
rank test was used to compare patient’s survival time between
groups. The Fisher exact and 2 tests were used to analyze the
association between two categorical variables. The Wilcoxon
rank-sum test was used for differences in median of age. The
Cox proportional hazards model was used for univariate analy-
sis to evaluate the association between survival time and risk
factors and for multivariate analysis to model the risks of IL-10
expression on survival time, with adjustment for clinical and
histopathological parameters (age, sex, race, tumor histology,
Table 1 IL-10 status in stage I NSCLC tumors according to clinicopathological features of patients
No. of patients
(n  138)
IL-10 expression
P
Positive
(n  94)
Negative
(n  44)
Age: median
(range)
64 (37–82) 64 (37–82) 65 (45–76) 0.28
Sex
Male 106 68 38 0.07
Female 32 26 6
Race
Caucasian 120 84 36 0.22
Other 18 10 8
Smoker
Yes 119 79 40 0.27a
No 9 8 1
Unknown 10 7 3
Histology of tumors
SCC 58 45 13 0.04
Adenocarcinoma
and others
80 49 31
TNM stage
T1N0M0 65 44 21 0.92
T2N0M0 73 50 23
5-year overall
survival rate
51.5% 56.6% 40.9%
(95% CI) (43.8%, 60.6%) (47.3%, 67.7%) (28.7%, 58.4%)
a P calculated comparing smoking vs. nonsmoking patients.
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and tumor size). All statistical tests are two sided, and a P 
0.05 was considered to be statistically significant.
All survival curves were calculated from the date of sur-
gery. Overall survival took all deaths (cancer related or not) into
account. Disease-specific survival time was calculated from the
date of surgery to death from cancer-related causes. Disease-free
survival time was calculated from the date of surgery to relapse
or death from cancer-related causes.
RESULTS
A total of 138 formalin-fixed, paraffin-embedded NSCLC
tumor specimens was stained using a standard immunohisto-
chemical technique reported previously for the identification of
IL-10 expression (18, 19). The usual pattern of positive staining
for IL-10 in NSCLC was cytoplasmic and not nuclear (Fig. 1,
A–C). Even if tumors cells were negative for IL-10 staining,
normal bronchial epithelial cells in the section were positive and
used as an internal positive control of the staining for IL-10. In
peribronchial gland cells or alveolar pneumocytes, IL-10 ex-
pression was not detectable. Lymphoid cells of tumor areas were
occasionally immunostained. Only 20 of 138 samples displayed
tumor-infiltrating lymphocytes, therefore hindering any relevant
analysis of IL-10 production by infiltrating immune cells. In the
positive control tissues (tonsil), the normal stratified squamous
epithelium displayed IL-10-positive cells. In the adjacent lymph
nodes, IL-10-positive cells were localized predominantly in the
germinal centers (data not shown). IL-10 immunohistochemical
staining showed a wide heterogeneity from rare scattered cells
to a homogeneous pattern for the vast majority of cells exam-
ined, suggesting that phenotypic heterogeneity is a major feature
in NSCLC (Fig. 1).
IL-10 expression was observed in 94 (68.1%) of the 138
stage I NSCLC specimens. Lack of staining was observed in 44
tumors (31.9%). Table 1 shows the relationships between the
expression of IL-10 and clinicopathological factors. There were
no statistically significant differences in TNM stage, sex, smok-
ing status, age, and race between the groups with IL-10-positive
and -negative staining. Interestingly, IL-10 expression was more
prevalent in the SCC subtype than it was in other histological
subtypes. Forty-five (77.6%) of the 58 cases of SCC exhibited
IL-10 expression, whereas 49 (61.3%) of 80 patients with non-
SCC tumors (mainly adenocarcinoma) showed IL-10 expression
(P  0.04; 2 test).
We subsequently analyzed the relationship between IL-10
expression and length of survival. The median follow-up time
for the patient population was 10.6 years. Fig. 2A shows the
Kaplan-Meier overall survival curves for patients whose tumors
were IL-10 positive and negative. Patients with tumors that were
Fig. 1 Immunohistochemical staining patterns of IL-10 in stage I NSCLC. A, a well-differentiated adenocarcinoma with most cancer cells expressing
IL-10 in the cytoplasm. B, a SCC with most carcinoma cells positive for IL-10. C, a bronchioalveolar carcinoma tumor with IL-10 expression. D, a
SCC tumor negative for IL-10 expression (original magnification, 400).
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IL-10 negative had a shorter survival time than did patients with
tumors that were IL-10 positive (P  0.08; Log-rank test).
Five-year overall survival rate for patients whose tumors were
IL-10 positive was 56.6% (95% CI  47.3–67.7%) and 40.9%
(95% CI  28.7–58.4%) for patients whose tumors were IL-10
negative (Table 1). Fig. 2B shows that patients with negative
IL-10 expression had significantly shorter disease-specific sur-
vival times than did patients with positive IL-10 expression
(P  0.02; Log-rank test). A comparison of disease-free sur-
vival curves in IL-10-negative and -positive patients yielded
similar results (P  0.05; Log-rank test; Fig. 2C). The prognos-
tic significance of IL-10 expression on disease-specific survival
was further explored in each major histological subtype. IL-10
negativity was a borderline significant adverse prognostic factor
among patients with non-SCC tumors (P  0.06; Log-rank test;
Fig. 3A). A similar trend was observed for patients with SCC of
the lung, but this trend was not significant (P  0.25; Log-rank
test; Fig. 3B). Univariate Cox proportional hazards model was
used to evaluate the association between IL-10, clinicopatho-
logical variables (age, sex, race, histological subtype, and
TNM), and survival time. Table 2 shows the results on disease-
specific survival. In multivariate Cox proportional hazards
model, among all clinicopathological variables, IL-10 expres-
sion was the only significant independent prognostic indicator
Fig. 2 Survival curves of patients with IL-10-positive and -negative NSCLC. The patients lacking IL-10 expression (solid line, n  44) had worst
outcomes than the patients with IL-10 expression (broken line, n  94) for overall (A), disease-specific (B), and disease-free survival (C).
Fig. 3 A, disease-specific sur-
vival curve of patients with
stage I SCC according to IL-10
expression; B, disease-specific
survival curve of patients with
adenocarcinoma or other histo-
logical subtypes according to
IL-10 expression.
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for disease-specific survival. The hazard of cancer death for
patients whose tumor was IL-10 positive was only 55% of the
hazard for patients whose tumor was IL-10 negative (P  0.04,
Cox model).
DISCUSSION
Human lung cancer displays an extremely aggressive clin-
ical course and represents the leading cause of malignancy-
related mortality in the United States (1). This behavior may
reflect an increased capacity to evade detection and containment
by host immune response. Because IL-10 demonstrates in vitro
immunosuppressive activities (9, 10), some groups have hypoth-
esized that IL-10 production by cancer cells may help the tumor
evade immunosurveillance (7, 8). Nevertheless, IL-10 is also
able to inhibit tumor growth and metastasis in various tumor
models (11–14). These conflicting results imply that it is all
about “fine tuning” in case of IL-10-mediated immunosuppres-
sion or immunostimulation. Because normal bronchial epithelial
cells constitutively express IL-10 (17), loss of IL-10 expression
by lung cancer cells would represent a specific change in the
tumor as compared with its normal epithelial counterpart. In the
present study, we explored the prognostic value of IL-10 ex-
pression by lung cancer cells in a large and homogeneous
population of 138 completely resected clinical/radiographic
stage I NSCLC for whom a median follow-up of 10.6 years was
available. We have demonstrated that IL-10 is retained in a
significant percentage of stage I NSCLCs. Overall, 94 (68.1%)
of 138 tumors expressed IL-10 in 10% tumor cells, whereas
loss of IL-10 expression was observed in 44 patients (31.9%).
Our data show that lack of IL-10 expression is a poor prognostic
factor in patients with stage I NSCLC. The poor prognostic
value of lack of IL-10 expression was observed for disease-
specific and -free survival, with a trend for overall survival.
Furthermore, multivariate analysis confirmed the independent
prognostic value of lack of IL-10 expression. The prognostic
value of IL-10 was retained even when we changed the cutoff
level of positivity from 10% (18) to 5 or 15%. Our results are in
contrast to a previous report by Hatanaka et al. (16), who
suggested that IL-10 expression by the tumor was an indicator
of poor prognosis. We have analyzed IL-10’s prognostic value
in a large and homogeneous population of patients with early
stage lung cancer (n  138), whereas Hatanaka et al. performed
their analysis using a smaller and more heterogeneous popula-
tion that included 82 patients with stage I–IIIb disease. Further-
more, the fact that all of the patients in our study were treated at
a single institution and received lengthy follow-up care after
surgery helps to increase the credibility of our survival analysis.
Finally, Hatanake et al. (16) evaluated IL-10 expression by
RT-PCR as opposed to immunohistochemistry in this study.
Thus, our different results may be related in part to differences
in patient population and the technique used to evaluate IL-10
expression. Indeed, we evaluated IL-10 expression at the protein
level as compared with the mRNA level for Hatanake et al.
Furthermore, both studies were retrospectively conducted and
therefore potentially subject to some degree of selection bias.
We have analyzed IL-10 expression by performing immu-
nohistochemical analysis with a polyclonal antihuman IL-10
antibody reported previously (18, 19). Other anti-IL-10 antibod-
ies have also been used to evaluate IL-10 expression in paraffin-
embedded tissue sections (17, 20). A good concordance between
reverse transcription-PCR analysis and immunohistochemical
analysis for IL-10 has been suggested in different reports (7,
17). We have used internal and external positive controls to
assess the specificity of the staining. We found that even if
tumor cells were negative for IL-10 staining, normal bronchial
epithelial cells in the section (when present) were positive (17),
thus ruling out a false negative result.
Although the mechanisms underlying the current data are
not clear, there are several potential explanations for the poor
outcome of patients with IL-10-negative tumors. Several labo-
ratories have demonstrated that IL-10 is a potent inhibitor of
tumor growth and metastasis in multiple animal models and
tumor types, including melanoma, breast and prostate cancers,
and Burkitt’s lymphoma (11, 13, 20, 21). In vivo, the effects of
IL-10 may be multifold. They can be related to direct inhibition
of IL-10 on the angiogenic process per se or indirectly by
affecting the angiogenic capacity or signals from tumor and/or
tumor-infiltrating cells. Compelling evidence indicates that the
antiangiogenic effect of IL-10 results from the inhibition of
angiogenic factor release and production by the tumor and/or
stromal cells. IL-10 induces production of TIMP-1, an inhibitor
of angiogenesis, and inhibits MMP-2 and MMP-9 secretion by
cancer cell lines, blocking the induction of microvessel forma-
tion in vitro (20, 22). It has also been suggested that IL-10 can
directly inhibit endothelial cell response to angiogenic factors
(21). Moreover, in murine mammary tumors, the antimetastatic
and antitumor activity resulting from IL-10 gene transfer is
related to enhanced production of nitric oxide (23).
One of the major roles of IL-10 in the regulation of im-
mune responses involves its deactivating effect on macrophages
(6). From the many cells and cell products within a tumor that
serve as inducers or modulators of angiogenesis, macrophages
Table 2 Univariate and multivariate Cox proportional hazards model on disease-specific survival
Univariate Multivariate
Hazard ratio 95% CI P Hazard ratio 95% CI P
Age 1.0 0.97–1.03 0.92
Sex (Male or female) 0.88 0.48–1.64 0.69
Race (Caucasian or other) 0.49 0.25–0.99 0.047 0.58 0.28–1.2 0.13
Histological subtype (SCC or other) 0.72 0.39–1.30 0.27
Tumor size (T1 or T2) 0.73 0.42–1.28 0.28
IL-10 ( or )a 0.51 0.29–0.89 0.02 0.55 0.31–0.98 0.04
a , IL-10 labeling index  10%; , IL-10 labeling index  10%.
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have emerged as a major component. IL-10 secreted by the
tumor cells may prevent the migration of macrophages from the
periphery into the tumor tissue, thus preventing macrophage
infiltration (24). IL-10 also inhibits the expression of angiogenic
factors (vascular endothelial growth factor, IL-1	, tumor necro-
sis factor-
, IL-6, and MMP-9) in tumor-associated macro-
phages (25). These changes correlate with decreased neovascu-
larization of the tumors. Alternatively, the inhibitory effect of
IL-10 on tumor metastasis has been suggested to be mediated
through a NK cell-dependent mechanism (6, 12). IL-10 is able
to affect the activities of NK cells, and NK cells were recently
shown to contribute to the antiangiogenic effects of IL-12
through the killing of endothelial cells (26).
The observation that IL-10 expression differs among his-
tological subtypes highlights the biological differences among
different subtypes of NSCLC. Different abnormalities in onco-
genes and tumor suppressor genes among histological subtypes
of NSCLC are well known. Indeed, K-ras mutations are much
more common in adenocarcinomas than in SCCs, whereas cy-
clin B1 overexpression or the p53 mutant immunophenotype is
more frequent in SCCs than in adenocarcinoma (2, 27, 28).
In conclusion, we found that a lack of IL-10 expression is
a prognostic factor of poor outcome in stage I NSCLC. This
result may be explained by the antitumor effects of IL-10, which
contrast with the immunomodulatory effects that this cytokine
displays in vitro. The mechanisms behind IL-10 antitumor ef-
fects might include inhibition of angiogenesis, stimulation of
TIMPs, inhibition of MMP secretion, and inhibition of macro-
phage activity (20–25). Nevertheless, this result needs to be
interpreted with caution because of potential limitations in the
present study: (a) IL-10 production by tumor-infiltrating lym-
phocytes was not addressed because only a small fraction of our
tissue samples displayed immune infiltrating cells; and (b) the
role of IL-10 in cancer progression or regression might be very
different according to the level of cytokine produced by the
tumor and infiltrating immune cells. Additional studies are
clearly required to confirm the present data and resolve the role
of IL-10 in tumor growth and metastasis. We plan to conduct
additional studies that will help in assessing the clinical impor-
tance of the present IL-10 findings and in understanding their
possible mechanisms. These studies will be conducted using
resected tissue from patients with stage I NSCLC, analyze the
expression of MMPs and TIMPs, microvessel density, and the
presence of tumor-infiltrating lymphocytes and their phenotype,
and relate these factors to IL-10 expression by the tumor and to
overall prognosis.
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